Biopsies and cell lines of NK/T-cell lymphoma, nasal-type (NKTCL) were subject to combined gene expression profiling and array-based comparative genomic hybridization analyses. Compared to PTCL, NOS, NKTCL had higher transcript levels for NK-cell markers and cytotoxic molecules, especially granzyme H, a novel sensitive biomarker of NKTCL.
INTRODUCTION
Several NK/T-cell lymphoma entities have a predilection for extranodal locations. One of the most common of these overall rare lymphoma entities is NK/T cell lymphoma, nasal type (NKTCL). The disease, most prevalent in Asian, Central and South American populations, most commonly arises in the nasal cavity or adjacent structures, but can also occur in other extranodal sites.
1 This lymphoma exhibits an angiocentric and angiodestructive growth pattern characteristically associated with necrosis and ulceration. The tumor cells typically express CD2, cytoplasmic CD3 (CD3ε chain) and CD56, are negative for CD5, CD4
and CD8 and have a cytotoxic immunophenotype with expression of perforin, granzyme B (gzm B), and T cell-restricted intracellular antigen (TiA1). Most cases derive from NK cells and lack T-cell receptor (TCR) gene rearrangement while a small proportion of cases have the phenotype and genotype of cytotoxic γδ or αβ T cells. Accordingly, the expression of killer immunoglobulin-like receptors (KIRs) has been documented in these tumors. 2 In virtually all cases, most neoplastic cells harbor clonal episomal Epstein-Barr virus (EBV), suggesting the implication of the virus in tumor pathogenesis. The genetic alterations of NKTCL reported in a few studies include gain on chromosome 2q, losses of chromosomes 6q and 1p, and occasional presence of isochromosome 7q. [3] [4] [5] [6] Even with intensive therapies combining multi-agent chemotherapy and involved field radiotherapy, the prognosis of NKTCL remains poor with 5-year overall survival ranging from 42% to 64% in four recent studies, [7] [8] [9] [10] and novel alternative approaches are needed.
Several factors have been incriminated to account for aggressiveness or poor outcome, including Fas and p53 mutations, 11, 12 expression of the multidrug resistance (MDR) 1 gene product P-glycoprotein, 13 absence of CD94 transcript 14 and gzm B inhibitor PI9. 9 However, the mechanisms involved in resistance to therapy remain poorly understood.
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Genome-wide profiling studies of NKTCL are scarse, 3, 15 likely reflecting not only the rarity of the disease, but also quantitative and qualitative restrictions imposed by small and often necrotic diagnostic samples. In one recent study, Iqbal et al. focused on in-depth genomic and transcriptomic analysis of specific chromosomal regions, which led them to identify candidate suppressor genes mapping to 6q. 5 In the current study, we analyzed a series of NKTCL samples in relation to normal cells and peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS), with the aims to (1) characterize the molecular signature of this lymphoma entity, (2) explore some signaling pathways implicated in its pathogenesis, and (3) search for novel markers potentially useful for diagnosis and/or targetable by therapeutic agents.
PATIENTS, MATERIALS AND METHODS

Patient characteristics and tumor samples
Nine newly diagnosed, previously untreated NKTCL patients with high quality RNA and/or DNA extracted from frozen tumor biopsies containing more than 60% tumor cells were selected for this study. Their main clinical, phenotypic and molecular characteristics are summarized in Table 1 . Seven tumors originated in the nasopharyngeal area, one in the skin, and one in the hypophysis. All cases were reviewed by three hematopathologists (L. The present study was approved by the institutional review board "Comité de Protection des Personnes Ile de France IX", Créteil, France.
Cell lines and normal NK cells
Two NKTCL cell lines, SNK6 and SNT8 (Table 1) , 16 and two samples of normal CD56+ NK cells purified from peripheral blood including resting and IL-2-activated NK cells, were also subjected to gene expression profiling. The MEC04 NKTCL cell line was also used for in vitro proliferation assay and immunohistochemical validation. 17 U937, a myelomonocytic cell line (ATCC LGC Standards, Molsheim, France), was used as control for in vitro assay. Cell lines were cultured in RPMI 1640 supplemented with 2 mM L-glutamine and 10% heatinactivated fetal bovine serum (Invitrogen, Carlsbad, CA) in the presence of 100 U/ml recombinant human IL-2, except for U937 cell line. Centrifugated pellets of SNK6 and MEC04 cells were fixed in ethanol to construct paraffin-embedded blocks.
RNA and DNA extraction
Total RNA was extracted with TRIZOL reagent (Invitrogen, Carlsbad, CA), according to the manufacturer's instructions, and DNA was extracted with phenol-chloroform using standard procedures. The integrity of the extracts was verified on an Agilent 2100 Bioanalyser (Agilent Technologies, Palo Alto, CA, USA).
Microarray procedures
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Microarray analyses were performed using 3 μ g total RNA as starting material and 10 μ g cRNA per hybridization (GeneChip Fluidics Station 400; Affymetrix, Santa Clara, CA). The total RNAs were amplified and labeled following the one-cycle target labeling protocol (http://www.affymetrix.com). The labeled cRNAs were hybridized to HG-U133 plus 2.0
Affymetrix GeneChip arrays (Affymetrix, Santa Clara, CA). The chips were scanned with an Affymetrix GeneChip Scanner 3000 and subsequent images analyzed using GCOS 1.4
(Affymetrix).
Gene expression analyses
The gene expression analysis encompassed HG-U133 plus 2.0 Affymetrix array data from seven NKTCL biopsies, two NKTCL cell lines (Table 1) , 16 PTCL, NOS recently reported by our group under accession number E-TABM-702, 18 six normal NK cells samples (including four previously published from GSE8059), 19 eighteen recently published normal B cell samples (eight from GSE15271 and 10 from GSE12195), 20, 21 and 15 activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL) samples from GSE12195. 21 Two NK cell samples without stimulation of IL-2 (one each from ours and from GSE8059) represented the "resting NK cell" group, while the two NK cell samples stimulated by IL-2 for 24 hours (one from our sample, the other from GSE8059) were regarded as the "activated NK cell" group.
Affymetrix raw data of the samples were normalized in batch using Robust Multichip Average (RMA) method along with 58 other samples unrelated to this study. The clustering analysis of the 25 tumor samples was performed as already described. 22 To identify genes differentially expressed between two groups of samples we used Welch's T-tests. To control for multiple testing, we measured the local false discovery rate using kerfdr R package, an alternative approach to the more commonly used Bonferroni and Benjamini-Hochberg methods. 23 The KEGG / Biocarta pathways enrichment scores were calculated by combining The mutations of PDGFRA exons 12, 14 and 18 were searched by Length Analysis of PCR Products (LAPP) and sequencing as described previously. 28 To search for mutations and polymorphisms in the PDGFRA promoter region, genomic DNA was amplified by PCR using the primers 1651F and 727R as described by Toepoel et al. 29 . After purification (PCR purification kit, GE Healthcare, Freiburg, Germany), automated sequencing was performed on the ABI310 genetic analyzer with the Big Dye terminator sequencing kit (Applied Biosystems) using the primers 1562F, 1340R, 1110F, and 759R (see supplementary data). Sequences were compared to the reference sequence for PDGFRA promoter (GenBank accession number X80389).
H thymidine-labeled proliferation assay
Cells were washed extensively to remove IL-2 and plated at 20,000 cells per well, in the presence or absence of imatinib mesylate (Axon Medchem BV, Groningen, The Netherlands), 
RESULTS
The molecular signature of NKTCL differs from that of normal NK cells
The Affymetrix expression profiles of seven NKTCL samples were compared with those of normal NK cells (n=6). A total of 2447 and 2339 probe sets corresponding to 1721 and 1436 overexpressed and underexpressed genes, respectively, significantly distinguished NKTCL tissues from normal NK cells (P < 0.005) ( Tables 2 and S1 (Tables 2   and S1 ). Interestingly, NKTCL appeared to be more closely related to activated than to resting NK cells, as the level of expression of about two-thirds of the NKTCL signature was closer to that of activated NK cells than that of resting NK cells.
Among these overexpressed genes tested by immunohistochemistry, E-cadherin, CD163, clusterin, EGFR, and cyclin D1 expression was restricted to non-neoplastic cells, i.e.
epithelial cells (E-cadherin, clusterin, cyclin D1, EGFR), stromal cells (clusterin, cyclin D1) and numerous histiocytes (CD163) ( Table 3) . By contrast, VCAM1 and the EBV-induced and oncogenes (MYC, RHOC). In addition to NCAM1 (CD56) and cytotoxic proteins such as TiA1 and gzm B which were strongly expressed in all NKTCLs, we investigated the expression of another cytotoxic granule-associated protein, gzm H, of which transcript levels were 13.66 times higher than in PTCLs, NOS. As shown in figure 1, a strong granular cytoplasmic staining was found in virtually all neoplastic cells of all NKTCL tumors tested (n=16) as well as in the SNK6 and MEC04 cells whereas gzm H was restricted to small lymphocytes in most PTCLs, NOS. Among PTCL, NOS, the γδ T-cell lymphoma was gzm H positive and another case disclosed heterogeneous partial staining.
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Patterns of copy number aberrations and identification of genes relevant to the pathobiology of NKTCL
The aCGH findings are summarized in Table 5 To identify candidate genes in the regions of CNA, we selected the genes with a
Welch's T-test P-value less than 0.001 and a fold average expression difference > 2.0 (or < 0.5) in NKTCL tissues compared to normal NK cells. The resulting list (Table S3) (increased transcript levels in four of six samples). These findings were independent of the presence or absence of 6q21 deletion.
Identification of distinct pathways in NKTCL
In order to identify potentially relevant biological pathways in NKTCL, four gene sets In order to evaluate the possible activation of pathways identified using statistical methods, the expression of several representative genes was assessed at the protein level (Table 3 and 
Activation of PDGFRA pathway in NKTCL
Since PDGFRα  a receptor tyrosine kinase mediating important cell functions such as migration, proliferation and cell survival and known to interact with PI3K/AKT and STAT proteins, 33 was highly expressed at the mRNA level (Table 2 and Figure 5B ), this factor was evaluated by immunohistochemistry. Eleven of 13 (85%) NKTCL cases showed cytoplasmic expression of PDGFRα. In addition, its phosphorylated form (pPDGFRα) was found in all 13
NKTCLs (Table 3 and Figure 1 ). In agreement with a recent report, 34 expression of both
PDGFRα and pPDGFRα was also demonstrated in most PTCLs, NOS (Table 3 ). In view of inserm-00462629, version 1 -10 Mar 2010
these findings, we investigated the potential implication of the PDGF signaling pathway in the proliferation of NKTCL cells. Imatinib mesylate induced dramatic concentration-dependent growth inhibition of PDGFRα-positive MEC04 cells whereas the effect on SNK6 cells was minimal. As shown in Figure 6 , a significant 50% growth inhibition was already observed when MECO4 cells were exposed to imatinib mesylate at 1µM that increased to 90% at 6 µM.
U937 used as a control cell line known to be resistant to imatinib mesylate maintained 63 % proliferation with 6 µM imatinib.
We further searched for potential genetic alterations underlying PDGFRA deregulation. The absence of copy number gain in PDGFRA locus validated by real-time PCR in eight interpretable samples was concordant with the absence of genomic imbalance in 4q11-q13 observed in our BAC array CGH data. In addition, we did not evidence mutations in exons 12, 14 and 18 of PDGFRA, in agreement with previous findings. 35 Finally, we performed mutations and polymorphisms analysis within the PDGFRA promoter region and in particular investigated the distribution of haplotypes which have been reported in association with different transcriptional activities. 36 Sequence analysis did not show any mutation in the nine samples tested (compared to the reference sequence), and the distribution in the haplotypes -four samples had a H1/H2α genotype, three H2α/H2α, one H2α/H2β and one H2α/H2γ − corresponded to that reported in the Western European population (see supplementary data).
DISCUSSION
In the present study, we characterized the molecular signature of NKTCL in comparison to normal NK cells and to PTCL, NOS. This led to the identification of deregulated genes and signaling pathways which might be relevant to the pathophysiology and clinicopathologic features of the disease and bring rationale for the development of new therapies.
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Unsupervised clustering remarkably segregated NKTCL and PTCL, NOS samples.
Notably, the NKTCL case with a T-cell cytotoxic phenotype (sample T5) clustered with those of NK cell origin, providing another molecular argument for grouping nasal "true NK-" and cytotoxic T-cell lymphomas as a single entity as proposed in the current WHO classification.
1 Interestingly, the NKTCL case of T-cell derivation also showed the 6q16-q25 deletion. The only mismatch was represented by one PTCL, NOS in the NKTCL cluster. That particular case had a γδ activated cytotoxic phenotype suggesting that derivation from the innate immune system might imprint a peculiar signature. 37 By comparison to PTCL, NOS, the molecular signature of NKTCL was significantly contributed by an overexpression of genes associated with cytotoxic functions and NK-cellassociated molecules. Interestingly, the highest fold change of expression was observed for gzm H transcripts. Granzyme H, a gzm family member sharing a 90% amino acid sequence identity with gzm B, is constitutively expressed in NK cells irrespective of their activation status 25 but acts differently from gzm B by inducing a caspase-independent cell death program. 38 We confirmed a strong gzm H protein expression in all NKTCLs contrasting with its negativity in most PTCLs, NOS, with the notable exception of the γδ T-cell lymphoma.
Therefore, gzm H appears to be a novel sensitive marker for NKTCL, although its specificity needs to be delineated with respect to its possible expression in other lymphomas derived from the innate immune system.
Other aspects of the NKTCL signature could be related to some peculiar clinicopathologic features of the disease. Angioinvasion and angiocentricity typical of NKTCL, might be accounted by the high expression of genes such as VCAM1, CXCL9, and CXCL10, encoding proteins involved in the interaction with endothelium or in the pathogenesis of tissue necrosis and vascular damage associated with EBV-positive lymphoproliferations. 39 NKTCL, which in most instances arises in the nasal area, is also
characterized by a strong tendency to disseminate to other extranodal distant sites. In view of the known roles of CCR7 and SELL/CD62L in peripheral lymph node homing and that of CCL27, CXCL12, in homing to the skin, intestine and bone marrow, it is likely that the lower levels of CCR7 and SELL/CD62L and the overexpression of CXCL12 might explain the pattern of distribution of the disease.
We confirmed here recurrent genomic gains and losses previously reported in NKTCL. Deletion of chromosome 6q reported as the most characteristic but not specific genetic alteration in NKTCL, [3] [4] [5] [40] [41] [42] was present in 40% of our cases, including SNK6 cell line. In line with the recent report by Iqbal et al., we also found recurrent gain of 1q21-q44
and loss of 17p13.3 in primary tumor samples. 5 These authors found PRDM1, ATG5, and AIM1 as target genes in the region of del6q21 and reported both mutation and methylation in
PRDM1.
Here, we further extended these previous findings by showing low levels of ATG5
and AIM1 transcripts in primary tumors. Conversely, PRDM1 showed a wide range of expression from case to case. In addition, we also found marked reduction in transcripts of HACE1, a gene encoding a novel E3 ubiquitin ligase, which is the target of epigenetic inactivation in Wilms' tumor and has been proposed as a tumor suppressor gene in multiple human cancers. Hace1 -/-mice are spontaneously prone to developing multiple malignant tumors in various organs. 43 Taken together, it is therefore tempting to speculate that HACE1 might be also involved in the pathogenesis of NKTCL.
The proto-oncogene MET mapping in 7q31, a region of recurrent gain in our series, was overexpressed in our samples. This receptor with tyrosine-kinase activity is a receptor to HGF, also overexpressed at the mRNA level in our NKTCL series. Interestingly, this pair of ligand-receptor appears to be linked to angiogenesis, tumor formation, invasion, and metastasis. 44 These findings, together with the expression of VEGFA and its receptor Altogether, these data provide strong arguments supporting the involvement of JAK-STAT and AKT pathways in NKTCL (Figure 7) .
EBV, constantly present in NKTCL, is suspected to play an important role in oncogenesis. Here we showed that, in comparison to EBV-negative normal NK cells, NKTCL overexpressed several EBV-induced genes. 15, 30 In agreement with a previous report, 24 one of these genes, EBI3, was validated at the protein level. Among the various mechanisms involved in NF-κB pathway, EBV is known to activate NF-κB pathway through LMP-1 and/or TRAF, effect on the SNK6 cell line, which might be related to a lower expression of PDGFRA, as suggested at the RNA level ( Figure 3 ). Although our results do not preclude the precise mechanism of action of imatinib and suggest heterogeneity in the sensitivity to the drug, the dramatic effect on MEC04 cells shed light on the possible use of tyrosine kinase inhibitors as a novel therapeutic option in some patients with NKTCL refractory to conventional therapies.
The cause of PDGFRA deregulation in NKTCL remains to be determined. We did not evidence either genomic imbalances or gene mutations. Furtheremore, mutations in the promoter region were absent in NKTCL primary tumors and cell lines, and we did not find overrepresentation of H2α haplotype, known to result in upregulation of PDGFRA in glioblastoma. 29 In conclusion, this integrative genomic and transcriptomic study characterizes the molecular signature of NKTCL, highlights emerging oncogenic pathways in this disease entity and offers rationale for exploring new therapeutic options such as tyrosine kinase inhibitors in patients with this aggressive malignancy. 
